Overview

Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare renal function of immunosuppressive regimens with different relevance of the calcineurin inhibitor (CNI) cyclosporine: standard dose CNI, low dose CNI, CNI free in de novo kidney transplant patients after 12 months of therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Basiliximab
Calcineurin Inhibitors
Cyclosporine
Cyclosporins
Everolimus
Mycophenolate mofetil
Mycophenolic Acid
Sirolimus